U.S. patent office drops pharma-disputed regs; FDA nixes broader use of Spectrum's Fusilev;

> The U.S. Patent and Trademark Office has dropped regulations that sparked a lawsuit by GlaxoSmithKline and the two sides have asked a court to dismiss the suit. Report

> FDA declined Spectrum Pharmaceuticals' request to broaden use of its drug, Fusilev, to treat advanced metastatic colorectal cancer. Report

> Sanofi-Aventis and Merck KGaA are among international drugmakers expected to bid for iNova Pharmaceuticals, the Australian Financial Review said. Report

> More reason for older patients to get the herpes zoster vaccine: Researchers found that adults who get singles have a 30 percent greater risk of developing a stroke. Report

> Zantac 75, the GlaxoSmithKline-owned heartburn brand, is launching a press and radio campaign to drive awareness and differentiate it from competitor brands. Report

Biotech News:

> Amgen looks to boost its R&D success rate. Article

> Avanir unveils promising late-stage Zenvia data. Article

> FDA staffers question Acorda's MS drug. Article

> Quebec to make $123M biopharma investment Article

> Kansas spurs early-stage drug development with $50M in VC funding Article

And Finally... Swine flu drove a 15-fold increase in intensive care admissions for viral lung inflammation in Australia and New Zealand, a study found. Report